Synonyms: AZD-4604 | AZD4604 | example 35 [WO2018134213A1] | Jak1-IN-7
Compound class:
Synthetic organic
Comment: This is a Janus kinase 1 (JAK1) inhibitor whose chemical structure was claimed in example 35 in Astrazeneca's patent WO2018134213A1 [1]. A first time disclosure made at the 2021 XXVI EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC) provided the AZD4604 name-to-structure association. AZD4604 is delivered by inhalation, and is proposed for anti-inflammatory action as an asthma therapy. The chemical structure matches the INN londamocitinib in proposed INN list 129 (August 2023).
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
AZD4604 is selective for JAK1 with >400-fold selectivity over JAK2 and >10,000-fold selectivity over JAK3 in enzymatic assays [1]. |
Selectivity at enzymes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|